CATX Logo

Perspective Therapeutics, Inc. Common Stock (CATX) Stock Forecast & Price Prediction

Live CATX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Medical Devices

$3.31

-0.10 (-2.93%)

12 Month Price Forecast For CATX

$3.31
Current Price
$223.71M
Market Cap
9 Ratings
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to CATX Price Forecasts

+534.4%
To High Target of $21.00
+383.4%
To Median Target of $16.00
+81.3%
To Low Target of $6.00

CATX Price Momentum

+0.3%
1 Week Change
-5.4%
1 Month Change
-63.2%
1 Year Change
+3.8%
Year-to-Date Change
-82.7%
From 52W High of $19.10
+22.6%
From 52W Low of $2.70

๐Ÿค” Considering Perspective Therapeutics (CATX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 10, 2025 2:18 PM UTC

CATX Analyst Ratings & Price Targets

Based on our analysis of 10 Wall Street analysts, CATX has a consensus that is bullish. The median price target is $16.00, with forecasts ranging from $6.00 to $21.00. Currently, there are 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings.

With CATX currently trading at $3.31, the median price forecast suggests a 383.4% upside. The most optimistic forecast comes from Nicole Germino at Truist Securities, projecting a 534.4% upside, while Alec Stranahan at B of A Securities provides the most conservative target, suggesting a 81.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CATX Analyst Consensus

8
Buy
1
Hold
0
Sell

CATX Price Target Range

Low
$6.00
Average
$16.00
High
$21.00
Current: $3.31

Latest CATX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CATX.

Date Firm Analyst Rating Change Price Target
Jan 14, 2025 RBC Capital Gregory Renza Outperform Reiterates $16.00
Nov 25, 2024 RBC Capital Gregory Renza Outperform Maintains $16.00
Nov 25, 2024 B of A Securities Alec Stranahan Neutral Downgrade $6.00
Nov 22, 2024 Oppenheimer Jeff Jones Outperform Maintains $16.00
Oct 24, 2024 Wedbush David Nierengarten Outperform Reiterates $20.00
Oct 24, 2024 UBS David Dai Buy Initiates $20.00
Oct 11, 2024 Oppenheimer Jeff Jones Outperform Reiterates $22.00
Oct 1, 2024 Wedbush David Nierengarten Outperform Initiates $25.00
Sep 25, 2024 Truist Securities Nicole Germino Buy Initiates $21.00
Sep 10, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Sep 9, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Sep 6, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Sep 3, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Aug 16, 2024 RBC Capital Gregory Renza Outperform Maintains $27.00
Aug 13, 2024 Oppenheimer Jeff Jones Outperform Maintains $17.00
Jul 25, 2024 B of A Securities Alec Stranahan Buy Initiates $24.00
Jun 25, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Jun 20, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00
Jun 18, 2024 Oppenheimer Jeff Jones Outperform Reiterates $0.00
Jun 18, 2024 Cantor Fitzgerald Louis Chen Overweight Reiterates $0.00

Stocks Similar to Perspective Therapeutics, Inc. Common Stock

The following stocks are similar to Perspective Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Perspective Therapeutics, Inc. Common Stock (CATX) Financial Data

Perspective Therapeutics, Inc. Common Stock has a market capitalization of $223.71M with a P/E ratio of -1.9x. The company generates $1.56M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is +33.7% quarter-over-quarter, while maintaining an operating margin of -5,049.9% and return on equity of -27.0%.

Valuation Metrics

Market Cap $223.71M
Enterprise Value $-39,864,244
P/E Ratio -1.9x
PEG Ratio -3.1x
Price/Sales 143.7x

Growth & Margins

Revenue Growth (YoY) +33.7%
Gross Margin N/A
Operating Margin -5,049.9%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +119.7%
Current Ratio 9.6x
Debt/Equity 1.3x
ROE -27.0%
ROA -14.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Perspective Therapeutics, Inc. Common Stock logo

Perspective Therapeutics, Inc. Common Stock (CATX) Company Overview

About Perspective Therapeutics, Inc. Common Stock

What They Do

Develops precision-targeted alpha therapies for oncology.

Business Model

The company focuses on developing and commercializing precision-targeted alpha therapies (TAT) to treat various types of cancer, particularly in patients with metastatic disease. Its primary revenue potential lies in the successful development and commercialization of its drug candidates, which are currently in clinical trials. Collaborations, such as the one with Bristol Myers Squibb, may also enhance its research capabilities and market reach.

Additional Information

Founded in 1998 and headquartered in Seattle, Washington, the company previously operated under the name Isoray, Inc. It is actively engaged in clinical trials for innovative treatments targeting specific cancer markers, aiming to provide effective options for patients who have not responded to existing therapies.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

116

CEO

Mr. Johan M. Spoor

Country

United States

IPO Year

2005

Perspective Therapeutics, Inc. Common Stock (CATX) Latest News & Analysis

CATX stock latest news image
Quick Summary

Perspective Therapeutics, Inc. will have its senior leadership team available for one-on-one meetings with investors at upcoming conferences, enhancing investor engagement opportunities.

Why It Matters

Perspective Therapeutics' participation in investor conferences signals engagement with the investment community, potentially boosting investor confidence and interest in the company's growth and innovations.

Source: GlobeNewsWire
Market Sentiment: Neutral
CATX stock latest news image
Quick Summary

Perspective Therapeutics reported positive interim results from its Phase 1/2a trial of [212Pb]VMT-ฮฑ-NET, showing a favorable safety profile and objective responses in some patients.

Why It Matters

Positive interim results from the Phase 1/2a study of [212Pb]VMT-ฮฑ-NET, showing safety and early objective responses, could enhance investor confidence and drive stock value for Perspective Therapeutics.

Source: GlobeNewsWire
Market Sentiment: Neutral
CATX stock latest news image
Quick Summary

Perspective Therapeutics, Inc. appointed Juan Graham as CFO effective January 6, 2025. Jonathan Hunt remains with the company as Chief Accounting Officer.

Why It Matters

Leadership changes, especially in key financial positions, can signal a shift in company strategy or stability, impacting investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
CATX stock latest news image
Quick Summary

Perspective Therapeutics is developing radiopharmaceuticals for oncology, focusing on theranostics to target tumors while minimizing healthy tissue damage. Their candidates VMT01 and VMT-ฮฑ-NET are in Phase 1/2 trials, with VMT01 receiving Fast Track Designation.

Why It Matters

Perspective Therapeutics' theranostics approach could revolutionize cancer treatment, enhancing efficacy and reducing side effects. Promising trials and Fast Track Designation could drive future growth.

Source: Seeking Alpha
Market Sentiment: Positive
CATX stock latest news image
Quick Summary

Perspective Therapeutics' alpha emitter PRRT demonstrates potential in early trials for GEP-NETs and melanoma, with manageable toxicity. The company has a strong cash position to support ongoing research.

Why It Matters

Perspective Therapeutics' promising trial results for PRRT may signal a breakthrough in cancer treatment, enhancing long-term research viability amid market skepticism and potential valuation recovery.

Source: Seeking Alpha
Market Sentiment: Neutral
CATX stock latest news image
Quick Summary

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced its senior leadership will attend upcoming investor conferences for one-on-one meetings with investors.

Why It Matters

Perspective Therapeutics' participation in investor conferences signals potential growth and transparency, attracting investor interest and possibly impacting stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About CATX Stock

What is Perspective Therapeutics, Inc. Common Stock's (CATX) stock forecast for 2025?

Based on our analysis of 10 Wall Street analysts, Perspective Therapeutics, Inc. Common Stock (CATX) has a median price target of $16.00. The highest price target is $21.00 and the lowest is $6.00.

Is CATX stock a good investment in 2025?

According to current analyst ratings, CATX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.31. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CATX stock?

Wall Street analysts predict CATX stock could reach $16.00 in the next 12 months. This represents a 383.4% increase from the current price of $3.31. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Perspective Therapeutics, Inc. Common Stock's business model?

The company focuses on developing and commercializing precision-targeted alpha therapies (TAT) to treat various types of cancer, particularly in patients with metastatic disease. Its primary revenue potential lies in the successful development and commercialization of its drug candidates, which are currently in clinical trials. Collaborations, such as the one with Bristol Myers Squibb, may also enhance its research capabilities and market reach.

What is the highest forecasted price for CATX Perspective Therapeutics, Inc. Common Stock?

The highest price target for CATX is $21.00 from Nicole Germino at Truist Securities, which represents a 534.4% increase from the current price of $3.31.

What is the lowest forecasted price for CATX Perspective Therapeutics, Inc. Common Stock?

The lowest price target for CATX is $6.00 from Alec Stranahan at B of A Securities, which represents a 81.3% increase from the current price of $3.31.

What is the overall CATX consensus from analysts for Perspective Therapeutics, Inc. Common Stock?

The overall analyst consensus for CATX is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.00.

How accurate are CATX stock price projections?

Stock price projections, including those for Perspective Therapeutics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.